Type 2 Diabetes Mellitus

📋 Key Information Summary

📋

Type 2 diabetes mellitus (T2DM) is characterised by progressive insulin resistance and relative insulin deficiency, accounting for approximately 85–90% of all diabetes in Australia.
An estimated 1.3 million Australians live with T2DM; prevalence in Aboriginal and Torres Strait Islander peoples is approximately 2–4 times higher than in non-Indigenous Australians.
Diagnosis requires a fasting plasma glucose (FPG) ≥7.0 mmol/L, HbA1c ≥6.5% (48 mmol/mol), or a 2-hour post-OGTT glucose ≥11.1 mmol/L, confirmed on two separate occasions (or a single test with symptoms).
Screening is recommended every 3 years from age 40 (or 18 for high-risk groups including ATSI peoples, those with gestational diabetes history, or PCOS).
Stepwise pharmacological management begins with metformin as first-line; SGLT2 inhibitors or GLP-1 receptor agonists are prioritised early in patients with established cardiovascular disease, heart failure, or CKD.
HbA1c target is generally ≤53 mmol/mol (7.0%); individualise to ≤48 mmol/mol (6.5%) in younger patients with short disease duration and no hypoglycaemia risk, or relax to ≤64 mmol/mol (8.0%) in frailty or limited life expectancy.
Annual comprehensive complication screening includes urine ACR, eGFR, retinopathy screening, foot assessment, and cardiovascular risk evaluation.
SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 RAs (semaglutide, liraglutide) have demonstrated cardiovascular and renal benefits independent of glycaemic control.
Insulin therapy should be considered when HbA1c remains above target despite dual or triple oral/injectable therapy; basal insulin is the preferred starting regimen.
Management of T2DM requires a multidisciplinary team approach including GP, endocrinologist, diabetes educator, dietitian, podiatrist, ophthalmologist, and psychologist.
Weight management of ≥5–10% body weight significantly improves glycaemic control, blood pressure, and cardiovascular risk.
Bariatric/metabolic surgery should be considered in adults with BMI ≥40 kg/m² (or ≥35 kg/m² with poorly controlled T2DM) when lifestyle and pharmacotherapy are insufficient.

🎧 Audio Brief

Protecting organs in modern metabolic care

A short clinical audio briefing generated from this article — perfect for the commute or ward round.

Introduction & Australian Epidemiology

Type 2 diabetes mellitus (T2DM) is a chronic, progressive metabolic disorder characterised by peripheral insulin resistance and a relative deficiency of insulin secretion from pancreatic beta cells. It is the most prevalent form of diabetes, accounting for approximately 85–90% of all diagnosed diabetes in Australia, and is strongly associated with obesity, metabolic syndrome, and sedentary lifestyle.

In Australia, an estimated 1.3 million people were living with T2DM in 2023, with prevalence continuing to rise due to ageing populations, increasing obesity rates, and improved case detection. T2DM is the seventh leading cause of death in Australia and a major contributor to cardiovascular disease, chronic kidney disease, lower-limb amputation, and preventable blindness.

The disease burden is not evenly distributed. Aboriginal and Torres Strait Islander peoples experience T2DM prevalence approximately 2–4 times greater than non-Indigenous Australians, with earlier onset, more aggressive complications, and higher mortality. Socioeconomic disadvantage, remote geography, and barriers to healthcare access compound these disparities.

The total direct cost of diabetes to the Australian healthcare system exceeds $6 billion annually, encompassing hospitalisations, medications (including PBS-listed agents and continuous glucose monitoring), allied health services, and management of complications.

⚠️

Clinical priority: T2DM is frequently diagnosed late — approximately 50% of patients already have evidence of at least one microvascular or macrovascular complication at the time of diagnosis. Early screening and timely intervention are essential to reduce long-term morbidity.

Pathophysiology & Risk Factors

The pathogenesis of T2DM is multifactorial and involves the interplay of genetic susceptibility, environmental factors, and behavioural determinants. The "ominous octet" framework describes eight key pathophysiological mechanisms contributing to hyperglycaemia.

Core Pathophysiological Mechanisms

Mechanism	Site	Clinical Consequence
Decreased insulin secretion	Pancreatic β-cells	Progressive β-cell failure; ~50% function lost at diagnosis
Increased hepatic glucose production	Liver	Fasting hyperglycaemia due to gluconeogenesis and glycogenolysis
Peripheral insulin resistance	Skeletal muscle, adipose tissue	Impaired glucose uptake; compensatory hyperinsulinaemia
Incretin defect	Gut (L-cells)	Reduced GLP-1 effect; impaired postprandial insulin release
Increased glucagon secretion	Pancreatic α-cells	Paradoxical hepatic glucose output postprandially
Increased renal glucose reabsorption	Kidney (SGLT2)	Raised renal threshold for glycosuria
Neurotransmitter dysfunction	Brain (hypothalamus)	Impaired appetite regulation and satiety signalling
Adipose tissue inflammation	Visceral fat	Chronic low-grade inflammation; lipotoxicity

Risk Factors for T2DM

Risk factors can be categorised as non-modifiable and modifiable. The Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) is a validated 10-item questionnaire used for population-level screening.

Non-Modifiable Risk Factors

Age ≥40 years (risk increases with age)
Family history of T2DM (first-degree relative)
Aboriginal or Torres Strait Islander descent
History of gestational diabetes mellitus (GDM)
Polycystic ovary syndrome (PCOS)
Certain ethnic backgrounds (South Asian, Pacific Islander, Māori, Middle Eastern)

Modifiable Risk Factors

Overweight/obesity (BMI ≥25 kg/m² or ≥23 kg/m² in Asian populations)
Central adiposity (waist circumference >94 cm men, >80 cm women)
Physical inactivity (<150 min moderate-intensity per week)
Unhealthy dietary patterns (high glycaemic index, ultra-processed foods)
Smoking
Impaired fasting glucose (IFG) or impaired glucose tolerance (IGT)
Hypertension, dyslipidaemia, obstructive sleep apnoea
Medications: corticosteroids, atypical antipsychotics, thiazides, statins

Diagnosis & Screening

Diagnostic Criteria

The diagnosis of T2DM is based on either symptoms of hyperglycaemia (polyuria, polydipsia, unexplained weight loss) combined with a random plasma glucose ≥11.1 mmol/L, or asymptomatic hyperglycaemia confirmed on two separate occasions. The following tests are accepted for diagnosis:

Test	Diabetes	Pre-diabetes	Normal
Fasting plasma glucose (FPG)	≥7.0 mmol/L	6.1–6.9 mmol/L	<6.1 mmol/L
2-hour post-OGTT glucose	≥11.1 mmol/L	7.8–11.0 mmol/L	<7.8 mmol/L
HbA1c (IFCC)	≥48 mmol/mol (6.5%)	42–47 mmol/mol (6.0–6.4%)	<42 mmol/mol (<6.0%)
Random plasma glucose	≥11.1 mmol/L (with symptoms)	—	—

⚠️

HbA1c limitations: HbA1c may be unreliable in the presence of haemoglobinopathies, iron deficiency anaemia, chronic kidney disease (eGFR <30 mL/min), haemolytic anaemia, pregnancy, or recent blood transfusion. In these situations, rely on FPG or OGTT.

Screening Recommendations

The Royal Australian College of General Practitioners (RACGP) and the Australian Diabetes Society (ADS) recommend opportunistic screening using FPG or HbA1c for the following groups:

1

General Population

Every 3 years from age 40. Use the AUSDRISK score to guide frequency: AUSDRISK ≥12 warrants screening every 1–2 years.

2

High-Risk Groups

Screen from age 18 in: ATSI peoples, those with GDM history, PCOS, high-risk ethnicities, or family history. Screen from age 30 in those with pre-diabetes.

3

Annual Screening

For those with pre-diabetes (IFG/IGT), BMI ≥30 kg/m², or those on diabetogenic medications (corticosteroids, antipsychotics).

Pharmacological Management (Stepwise)

Pharmacotherapy for T2DM follows a stepwise approach aligned with the ADA/EASD consensus, RACGP guidelines, and Australian PBS availability. Lifestyle modification remains the foundation at every step. Agents are selected based on glycaemic efficacy, cardiovascular and renal benefit, hypoglycaemia risk, effect on weight, cost, and patient preference.

🚨

Priority recommendation: In patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure (HFrEF or HFpEF), or chronic kidney disease (eGFR 20–60 mL/min or albuminuria), an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular/renal benefit should be initiated independent of HbA1c and regardless of metformin use.

Step 1 — Lifestyle Modification + Metformin

Metformin remains the first-line pharmacological agent for T2DM unless contraindicated (eGFR <30 mL/min) or not tolerated.

💊

Metformin

Diabex® · Diaformin® · Glucophage® · Biguanide

Adult dose Start 500 mg PO daily with food; titrate over 2–4 weeks to 1 g BD (max 2.5–3 g/day in divided doses)

Paediatric dose ≥10 years: 500 mg daily, titrate to 1 g BD (max 2 g/day)

Route / Frequency Oral, with meals (BD or TDS)

Renal adjustment eGFR 30–45: max 1 g/day; eGFR <30: contraindicated. Hold before iodinated contrast.

Key ADRs GI upset (diarrhoea, nausea) — mitigated by slow titration or XR formulation; rare lactic acidosis; B12 deficiency with prolonged use

PBS status ✔ PBS General Benefit

Step 2 — Dual Therapy

If HbA1c remains above target after 3–6 months on metformin, add a second agent. Choice is guided by comorbidities:

If CVD/HF/CKD

SGLT2i or GLP-1 RA

Prioritise agents with proven cardiorenal benefit regardless of HbA1c.

Setting: GP with specialist guidance

Weight concern

GLP-1 RA or SGLT2i

Both classes promote weight loss (GLP-1 RA 3–7 kg; SGLT2i 2–3 kg).

Setting: GP, endocrinologist

Hypoglycaemia avoidance

DPP-4i, SGLT2i, or TZD

Avoid sulfonylureas in those at high hypoglycaemia risk (elderly, erratic meals, renal impairment).

Setting: GP

Second-Line Agents

💊

Empagliflozin

Jardiance® · SGLT2 inhibitor

Adult dose 10 mg PO daily (can increase to 25 mg daily)

CV / Renal benefit EMPA-REG OUTCOME: 14% reduction in MACE; 39% reduction in HF hospitalisation. EMPA-KIDNEY: 28% reduction in CKD progression.

Renal adjustment Initiate if eGFR ≥20 mL/min for cardiorenal benefit; glycaemic efficacy reduced at eGFR <45

Key ADRs Genital mycotic infections, UTI, euglycaemic DKA (rare), volume depletion

PBS status ✔ PBS Restricted Benefit

💊

Dapagliflozin

Forxiga® · SGLT2 inhibitor

Adult dose 10 mg PO daily

CV / Renal benefit DECLARE-TIMI 58: reduced HF hospitalisation. DAPA-CKD: 39% reduction in CKD progression. DAPA-HF: 26% reduction in composite CV death/HF hospitalisation.

Renal adjustment Initiate if eGFR ≥20 mL/min (CKD/HF); glycaemic efficacy reduced at eGFR <45

PBS status ✔ PBS Restricted Benefit

💊

Semaglutide (subcutaneous)

Ozempic® · GLP-1 receptor agonist

Adult dose Start 0.25 mg SC weekly × 4 weeks; titrate to 0.5 mg weekly, then 1 mg weekly (max 2 mg/week)

CV benefit SUSTAIN-6: 26% reduction in MACE. SELECT trial: 20% MACE reduction in overweight/obesity without diabetes.

Weight loss Approximately 5–7 kg at 1 mg/week

Key ADRs Nausea, vomiting, diarrhoea (transient); risk of pancreatitis; contraindicated in MEN2/MTC

PBS status ✔ PBS Restricted Benefit

💊

Sitagliptin

Januvia® · DPP-4 inhibitor

Adult dose 100 mg PO daily (50 mg if eGFR 30–50; 25 mg if eGFR <30)

CV evidence TECOS: cardiovascular safety established; no superiority

Key ADRs Well tolerated; rare arthralgia, bullous pemphigoid, acute pancreatitis

PBS status ✔ PBS General Benefit

💊

Glimepiride

Amaryl® · Sulfonylurea

Adult dose Start 1 mg PO daily; titrate to max 4–6 mg daily

Key ADRs Hypoglycaemia (especially elderly, renal impairment); weight gain (1–2 kg)

Renal adjustment Use with caution if eGFR <60; start low, monitor closely

PBS status ✔ PBS General Benefit

Step 3 — Triple Therapy

If dual therapy does not achieve target HbA1c after 3–6 months, a third agent from a complementary class is added. Common combinations include metformin + SGLT2i + GLP-1 RA, or metformin + SGLT2i + DPP-4i (note: do not combine GLP-1 RA with DPP-4i).

Step 4 — Insulin Therapy

Insulin should be initiated when HbA1c remains above target despite optimised oral/injectable therapy, or when HbA1c is >86 mmol/mol (10%) at presentation. Basal insulin is the preferred starting regimen.

💉

Insulin glargine

Lantus® · Toujeo® · Basal insulin analogue

Adult dose Start 10 units or 0.1–0.2 units/kg SC at bedtime; titrate by 2–4 units every 3–7 days to fasting glucose target (4.4–7.0 mmol/L)

Duration Up to 24 hours (glargine U100); up to 36 hours (glargine U300)

Key ADRs Hypoglycaemia, weight gain, injection site reactions

PBS status ✔ PBS General Benefit

💉

Insulin degludec + liraglutide

Xultophy® · Fixed-ratio combination

Adult dose Start 10 dose steps SC daily; titrate by 2 dose steps every 3–4 days (max 50 dose steps/day)

Advantage Combines basal insulin with GLP-1 RA; less weight gain and hypoglycaemia vs basal-bolus

PBS status ✔ PBS Restricted Benefit

Step 5 — Intensified Insulin Regimens

If basal insulin + oral agents fail to achieve target, consider basal-bolus insulin (adding rapid-acting insulin before meals) or a premixed insulin regimen. Continuous subcutaneous insulin infusion (CSII / insulin pump) is rarely indicated in T2DM but may be considered in select patients with persistent hyperglycaemia despite multiple daily injections.

Additional Agent Considerations

💊

Pioglitazone

Actos® · Thiazolidinedione

Adult dose 15–45 mg PO daily

Key ADRs Fluid retention, weight gain, increased fracture risk, possible bladder cancer risk

PBS status ✔ PBS General Benefit

💊

Tirzepatide

Mounjaro® · Dual GIP/GLP-1 RA

Adult dose Start 2.5 mg SC weekly × 4 weeks; titrate to 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg weekly

Efficacy SURPASS trials: HbA1c reduction up to 2.4%; weight loss up to 12.4 kg

PBS status ✘ Not PBS-listed for T2DM

Complications & Glycaemic Targets

Glycaemic Targets

Glycaemic targets should be individualised based on patient age, duration of diabetes, life expectancy, hypoglycaemia risk, comorbidities, and patient preference. HbA1c is the primary monitoring metric.

Tight Control

HbA1c ≤48 mmol/mol (6.5%)

Younger patients, short duration of diabetes, no significant comorbidities, no hypoglycaemia risk. Metformin alone may achieve this target.

Setting: GP with regular monitoring

Standard Target

HbA1c ≤53 mmol/mol (7.0%)

Appropriate for most adults with T2DM. Balances glycaemic benefit with risk of hypoglycaemia and treatment burden.

Setting: GP / shared care

Relaxed Target

HbA1c ≤64 mmol/mol (8.0%)

Elderly/frail patients, limited life expectancy (<5 years), significant comorbidities, long-standing diabetes with established complications, high hypoglycaemia risk.

Setting: GP, geriatrician

Microvascular Complications

Complication	Screening	Key Management
Diabetic retinopathy	Annual fundal photography from diagnosis (2-yearly if low risk). MBS item 10953.	Optimise HbA1c, BP, lipids. Intravitreal anti-VEGF (ranibizumab, aflibercept) for proliferative/DME. Refer ophthalmology.
Diabetic nephropathy	Annual urine ACR + eGFR from diagnosis. Repeat abnormal results within 3 months.	ACEi or ARB for albuminuria. SGLT2i (eGFR ≥20). Finerenone for CKD with albuminuria. BP target <130/80 mmHg.
Diabetic neuropathy	Annual 10 g monofilament + 128 Hz tuning fork assessment.	Painful neuropathy: pregabalin, duloxetine, or amitriptyline. Gabapentin as alternative. Foot ulcer prevention.

Macrovascular Risk Management

Cardiovascular disease is the leading cause of death in people with T2DM. Comprehensive cardiovascular risk reduction requires a multifactorial approach:

1

Blood Pressure

Target <130/80 mmHg. First-line: ACE inhibitor or ARB (especially if albuminuria). Add amlodipine or indapamide as second/third-line.

2

Lipid Management

Statin therapy for all patients aged >50 (or >35 in ATSI peoples). High-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) if high CV risk. Add ezetimibe if LDL not at target.

3

Antiplatelet Therapy

Aspirin 75–100 mg daily for secondary prevention. Primary prevention: consider in high-CV-risk patients (10-year risk >15%) after discussing bleeding risk.

4

Smoking Cessation

Absolute priority. Offer NRT, varenicline, or bupropion. Refer to Quitline (13 7848). PBS-subsidised cessation aids available.

Diabetic Foot Disease

⚠️

Critical: Diabetes-related foot disease is the leading cause of non-traumatic lower-limb amputation in Australia. All patients should undergo annual foot risk assessment. Referral to a multidisciplinary diabetic foot team is required for any ulceration, infection, or critical limb ischaemia. High-risk patients should receive podiatry every 6–8 weeks.

Essential Annual urine albumin-to-creatinine ratio (ACR) MBS item 66827. Detect early nephropathy.

Essential eGFR (serum creatinine) MBS item 66829. Monitor renal function; guide drug dosing.

Essential HbA1c (every 3–6 months) MBS item 66841. Quarterly until stable, then 6-monthly.

Available Fasting lipid profile Annual. MBS item 66823.

Available Fundal photography / retinal screening Annual. MBS item 10953. Non-mydriatic cameras widely available.

Available FBC, LFTs, TSH Baseline and as clinically indicated. LFTs before metformin/pioglitazone.

Specialist Continuous glucose monitoring (CGM) Consider in patients on insulin. FreeStyle Libre / Dexcom. PBS-listed for T1DM; available privately for T2DM.

Annual Review Checklist

Component	Assessment	Frequency
HbA1c	Glycaemic control	3–6 monthly
Blood pressure	Target <130/80 mmHg	Every visit
Lipid profile	LDL target per CV risk	Annual
Urine ACR + eGFR	Renal function / albuminuria	Annual
Retinal screening	Diabetic retinopathy	Annual
Foot examination	Monofilament + pulse + visual	Annual (high risk: every visit)
Weight / BMI / waist	Obesity management	Every visit
Depression screening	PHQ-9 or K10	Annual
CVD risk assessment	Australian absolute CVD risk calculator	Every 2 years (or as needed)
Immunisation review	Influenza (annual), pneumococcal, COVID-19, hepatitis B	Annual review

Special Populations

🤰

Pregnancy

Metformin: May be continued in pregnancy (off-label but widely used); discuss with obstetric team.

Insulin: Insulin glargine, detemir, or aspart are preferred. NPH insulin also safe. Tight control essential (HbA1c <48 mmol/mol pre-conception if safe).

Contraindicated: All SGLT2 inhibitors, GLP-1 RAs, DPP-4 inhibitors, statins, ACE inhibitors, ARBs — cease before or at confirmation of pregnancy.

Pre-conception counselling is essential. Folic acid 5 mg daily (higher dose). Multidisciplinary diabetes-in-pregnancy clinic preferred.

👶

Paediatrics

Metformin: Approved from age 10 for paediatric T2DM. Dose: 500 mg daily, titrate to 1 g BD.

Insulin: If HbA1c >69 mmol/mol (8.5%) at presentation or symptomatic hyperglycaemia. Basal-bolus or CSII.

Paediatric T2DM is increasingly common in Australia, especially in ATSI adolescents. Specialist paediatric endocrinology involvement is recommended. Lifestyle intervention is paramount.

👴

Elderly / Frail

HbA1c target: Relax to ≤64 mmol/mol (8.0%) or individualise further. Avoid tight targets that risk hypoglycaemia.

Preferred agents: DPP-4 inhibitors (sitagliptin, linagliptin) — weight neutral, low hypoglycaemia risk. Avoid sulfonylureas.

Deprescribing: Consider reducing medication burden. Simplify regimens. Prioritise quality of life.

Falls prevention is critical. Hypoglycaemia in the elderly can present as confusion, falls, or stroke mimic. Educate carers.

🫘

Chronic Kidney Disease

Metformin: Reduce to max 1 g/day if eGFR 30–45; cease if eGFR <30.

SGLT2 inhibitors: Can initiate for cardiorenal benefit if eGFR ≥20. Glycaemic effect diminishes but organ protection persists.

GLP-1 RAs: No dose adjustment needed for semaglutide or dulaglutide in CKD. Preferred in advanced CKD.

Insulin: Reduced clearance in CKD — increase hypoglycaemia monitoring. Consider dose reduction.

Finerenone (Kerendia®) — selective non-steroidal MRA — reduces CKD progression and CV events in T2DM with albuminuria. PBS Authority Required.

🫁

Hepatic Impairment

Metformin: Avoid in severe hepatic impairment (Child-Pugh C). Caution in cirrhosis due to lactic acidosis risk.

Pioglitazone: Effective for NAFLD/NASH but contraindicated in active liver disease or ALT >2.5× ULN.

Preferred agents: DPP-4 inhibitors (no hepatic dose adjustment). Insulin may be required.

Monitor LFTs. NAFLD is present in up to 70% of T2DM patients. Screen with FIB-4 score; refer hepatology if elevated.

🛡️

Immunocompromised

Corticosteroid-induced diabetes: Common in transplant recipients and those on high-dose steroids. May require sliding-scale insulin.

SGLT2 inhibitors: Increased risk of genital mycotic infections and UTIs — use with caution in immunosuppressed patients.

Ensure up-to-date immunisations (influenza, pneumococcal, hepatitis B, COVID-19). Coordinate with immunology/transplant team.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiology

T2DM prevalence in ATSI peoples is approximately 2–4 times that of non-Indigenous Australians. Onset is often earlier (from age 25+), complications develop more rapidly, and diabetes-related mortality is significantly higher.

Screening

Commence screening from age 18 (or earlier if risk factors present). AUSDRISK is validated for ATSI populations. Point-of-care HbA1c (POC-A1c) is available via the national QAAMS programme for remote communities.

Remote access

Remote and very remote ATSI communities face limited access to endocrinology specialists, diabetes educators, ophthalmology, and podiatry. Telehealth has expanded significantly since 2020. Aboriginal Medical Services (AMS) and Remote Area Health Corps (RAHC) provide primary care. Specialist outreach services (e.g., RFDS) offer ophthalmology and endocrinology clinics.

PBS access

Closing the Gap (CTG) PBS co-payment measure provides PBS medicines at no cost or reduced cost for eligible ATSI patients. SGLT2 inhibitors and GLP-1 RAs are accessible under CTG. Ensure CTG eligibility is confirmed at each prescription.

Cultural safety

Engage Aboriginal Health Workers (AHWs) and Aboriginal Health Practitioners (AHPs) in care planning. Use culturally appropriate education materials. Respect kinship systems and community obligations. Yarning-based approaches improve engagement and self-management.

Comorbidities

ATSI peoples with T2DM have higher rates of concurrent CKD, CVD, peripheral vascular disease, and diabetic foot complications. Ensure annual cycle-of-care is completed. ATSI-specific absolute cardiovascular risk calculators should be used.

Food security

Remote communities may have limited access to fresh, affordable, and culturally appropriate food. Nutritional advice must account for locally available options. The Australian Government's Stores Policy and community store licensing aim to improve healthy food availability.

Resources & referrals

RHDAustralia (rhdaustralia.org.au) provides T2DM and RHD resources. The National Aboriginal Community Controlled Health Organisation (NACCHO) coordinates AMS networks. The TACKER programme supports diabetes management in ATSI communities. Refer to local AMS for integrated, culturally safe care.

📚 References

1. Royal Australian College of General Practitioners. General practice management of type 2 diabetes: 2024–2025. East Melbourne: RACGP; 2024.
2. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1):S1–S321.
3. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022: a consensus report by the ADA and EASD. Diabetologia. 2022;65(12):1925–1966.
4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373(22):2117–2128.
5. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436–1446.
6. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834–1844.
7. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD). N Engl J Med. 2020;383(23):2219–2229.
8. Australian Institute of Health and Welfare. Diabetes: Australian facts. Canberra: AIHW; 2023. Cat. no. CVD 82.
9. Department of Health and Aged Care. National Diabetes Strategy 2021–2030. Canberra: Australian Government; 2021.
10. Wabe NT, Thomas J, Seo D, et al. Type 2 diabetes prevalence and management in Aboriginal and Torres Strait Islander peoples: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2023;203:110866.
11. Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
12. Lipscombe L, Butalia S, Dasgupta K, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2023 update. Can J Diabetes. 2023;47(7):558–576.